An interventional study of Acupressure and Sham Acupressure in Diabetes Mellitus and Acupressure, sponsored by Abant Izzet Baysal University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Abant Izzet Baysal University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 246 studies in Diabetes Mellitus with a site in Turkey — 37 open to participants now, 44 under way, 1 of them phase 3. Diabetes Mellitus · Turkey.
Among the 246 studies in Diabetes Mellitus with a site in Turkey, this one is the 125th largest by planned enrollment of the 147 interventional ones that give a count, is one of 18 that started in 2026, is one of 92 with no phase, reaches primary completion later than 28 of the 43 other live ones, and was the 224th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →37 of the 246 studies in Diabetes Mellitus with a site in Turkey are open now. Recruiting first, the newest first:
Aylin DEMİR · Sites in Turkey
Ages 35–65
Bilecik Seyh Edebali Universitesi · Sites in Turkey
Ages 18–65
Kırıkkale University · Sites in Turkey
Ages 30–75 · Men only · Healthy volunteers
Ataturk University · Sites in Turkey
Ages 50–80 · Healthy volunteers
Ege University · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
246 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 38 · Phase 4 15
First in 2002; this study’s year is marked. 18 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 90 across the 147 interventional studies, 120 across the 97 observational. Of the 192 that completed or were terminated, 45 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 246 have an industry lead sponsor. The 10 most frequent:
Abant Izzet Baysal University is the lead sponsor of 250 studies on the registry; 58 are open to participants now.
Abant Izzet Baysal University has 8 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
8 of the studies in Diabetes Mellitus with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07491185Ege UniversityEffect of Glycemic Control on Intraoperative NIRS and Postoperative Recovery in Diabetic Patients | 2026-11 |
| NCT07444697Kırıkkale University"Erectile Function After PCI in MI and Non-MI Patients" | 2026-11 |
| NCT07734428Istanbul Bilgi UniversityInflammation and Diabetes: Evaluating Antioxidant Levels | 2026-12-30 |
| NCT07329985Bilecik Seyh Edebali UniversitesiFEAR of HYPOGLYCEMIA in PATIENTS WITH DIABETES | 2027-01-15 |
| NCT07905274Bandırma Onyedi Eylül UniversitySarcopenia Risk in Obese T2DM Patients | 2027-03-20 |
Add all 8 to your calendar (.ics) → With an account.
Among the 246 studies in Diabetes Mellitus with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the effects of acupressure on blood glucose levels and anxiety in older adults with diabetes. A three-arm randomized controlled trial will be conducted, comparing acupressure, sham acupressure, and routine care groups. Fasting and postprandial blood glucose levels will be assessed as primary outcomes, and state anxiety will be assessed as a secondary outcome.
Diabetes is a common chronic disease in older adults and may be associated with difficulties in maintaining optimal blood glucose levels and increased anxiety. This study is designed to evaluate the effects of acupressure on blood glucose levels and anxiety in older adults with diabetes. This is a three-arm, parallel-group, double-blind randomized controlled trial. Participants will be randomly assigned in a 1:1:1 ratio to an acupressure group, a sham acupressure group, or a routine care control group. Participants in the intervention group will receive acupressure applied to the HT7, SP6, and ST36 acupoints by a trained researcher. The intervention will be administered once daily for six sessions, with each session lasting approximately 15-20 minutes. The sham acupressure group will receive light pressure applied to non-acupoint areas near the same anatomical regions, while the control group will continue to receive routine clinical care without any additional intervention. The primary outcome of the study is blood glucose level, assessed using fasting and postprandial capillary blood glucose measurements at baseline and at predefined time points during the intervention period. Secondary outcomes include anxiety levels, measured using the State-Trait Anxiety Inventory.Outcome assessments will be conducted by assessors blinded to group allocation. Prior to the main trial, a pilot study will be conducted to evaluate the feasibility of the intervention protocol and data collection procedures, and to estimate the effect size required for calculating the final sample size of the main study. Findings from the pilot study will be used to refine the intervention procedures and to determine the final sample size. Participants included in the pilot study will not be included in the main trial.
The criteria were revised on the registry on Oct 9, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants assigned to this group will receive acupressure treatment at points HT7, SP6, and ST36 by a trained researcher. The intervention will be administered once daily for six days, in addition to routine clinical care, with each session lasting approximately 15-20 minutes.
Other: Acupressure
Participants assigned to this group will receive sham acupressure, consisting of light pressure applied to non-acupoint areas near the same anatomical regions as the intervention group.
Other: Sham Acupressure
Participants assigned to this group will receive routine clinical care only and will not receive any additional intervention during the study period.
Other: Routine care
The acupressure intervention will be conducted in a designated room at the institution, once daily for 6 consecutive days, with each session lasting 15-20 minutes, totaling 6 sessions. During the first 3-5 minutes of each session, participants will be guided to the appropriate position and approached to ensure comfort. Acupressure will then be applied to a total of six points: both wrists (HT7) and both legs (ST36, SP6), with two points on each limb. Each of the six points will receive a 30-second preparation followed by 2 minutes of acupressure application
Participants in the placebo group will receive sham acupressure administered by the researcher in a quiet, designated room at the institution, once daily for 6 consecutive days, with each session lasting 15-20 minutes, totaling 6 sessions. Pressure will be applied to bony areas approximately 1.5-2 cm away from the HT7, SP6, and ST36 points, where no meridians pass. In the intervention group, evaluation will be made at the specified frequency, using the same measurement tools and the same measurement methods.
Participants will receive routine clinical care only and no additional intervention.
Blood Glucose
Participants' blood glucose results will be assessed by capillary blood glucose measurement after at least 8-10 hours of fasting and 2 hours after meals. Measurement Process: Fasting blood sugar measurement: Fasting blood glucose measurement: This will be assessed before the start of the treatment, 24 hours after the completion of 3 sessions, and 24 hours after the completion of 6 sessions, after an 8-10 hour fast. Postprandial blood glucose measurement: Postprandial blood glucose levels will be assessed at the 2nd hour after the first bite of the meal. The first postprandial blood glucose assessment will take into account the first main meal after the first session, the second assessment will take into account the first main meal after the 3rd session, and the third assessment will take into account the postprandial blood glucose levels measured at the first main meal after the 6th session.
Time frame: Baseline to Day 6
Anxiety
Anxiety levels will be assessed using the Spielberger State-Trait Anxiety Inventory (STAI). The Spielberger State-Trait Anxiety Inventory (STAI) is a validated self-report questionnaire used to assess anxiety. It consists of two distinct subscales: State Anxiety (STAI-S), which measures temporary anxiety related to the individual's current condition, and Trait Anxiety (STAI-T), which measures a person's general and long-term tendency to experience anxiety. Each subscale includes 20 items, with total scores ranging from 20 to 80. Higher scores indicate higher levels of anxiety, while lower scores indicate lower anxiety levels. Measurement Process: Before the intervention, the Spielberger State-Trait Anxiety Inventory (STAI) will be administered. The Spielberger State Anxiety Inventory will be applied to the participants half an hour after the first session, before the sixth session, and half an hour after the completion of the sixth session to assess their current anxiety levels.
Time frame: Baseline to Day 6
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2026 to primary completion in Aug 2026, 6 months.
Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 6 months is below that.
Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Feb 2026, on Oct 9, 2026.
Primary completion moved once since we started tracking on Sep 25, 2026: Apr 2026 → Aug 2026, on Oct 9, 2026.
Completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Nov 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abant Izzet Baysal University →